Pharvaris N.V. (PHVS) Stock
PHVS has an Alpha Score of 65 out of 100 (moderate), computed on Aug 23, 2026 from 3 of 4 sub-scores. Company insiders reported 0 open-market buys and 19 sales on SEC Form 4 in the 90 days to Oct 21, 2026.
What is PHVS's Alpha Score?
How it works →Alpha Score of 65 reflects moderate overall profile with strong momentum, strong value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Aug 23, 2026 · 60 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Are Pharvaris N.V. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 23, 26 | Monges Viviane | Director | SELL | 12.0K | $396K |
| Sep 22, 26 | Schikan Johannes Gerardus Christiaan Petrus | Director | SELL | 800 | $29K |
| Sep 21, 26 | Nassif David W. | CFO / CLO | SELL | 6.0K | $219K |
| Sep 17, 26 | Lesage Anne | Chief Early Development | SELL | 20.0K | $765K |
| Sep 17, 26 | Glassman Robert | Director | SELL | 14.5K | $559K |
| Sep 17, 26 | Bjork Elisabeth | Director | SELL | 52.5K | $2.0M |
| Sep 17, 26 | Schikan Johannes Gerardus Christiaan Petrus | Director | SELL | 200.0K | $7.0M |
| Sep 17, 26 | Lu Peng | President | SELL | 100.0K | $3.5M |
| Sep 15, 26 | Souverijns Wim | Chief Commercial Officer | SELL | 6.1K | $237K |
| Sep 15, 26 | Glassman Robert | Director | SELL | 8.7K | $332K |
SEC Form 4 filings as of Oct 21, 2026
See cluster-buy signals across all tickers →What are PHVS's key statistics?
Key statistics as of Oct 21, 2026
PHVS price chart
Powered by TradingViewWhat does Pharvaris N.V. do?
Pharvaris N.V. is a biopharmaceutical company that specializes in discovering, developing, and commercializing innovative therapies to treat hereditary angioedema (HAE) and other bradykinin B2 receptor-mediated diseases. With its headquarters in Leiden, the Netherlands, Pharvaris is prominently focused on addressing unmet medical needs within the biopharmaceutical industry. The company's key product candidates are designed to provide an oral alternative to injectable therapies for HAE, promising convenience and broader accessibility for patients. Through its research and development efforts, Pharvaris contributes significantly to the healthcare sector by advancing treatment options for rare genetic conditions. Its innovative approach to treatment aims to enhance patient quality of life and improve therapeutic outcomes. As a player in the biotechnology domain, Pharvaris is integral to ongoing developments in genetic and rare disease treatments, reflecting the increasing significance and demand for targeted medicinal solutions in modern healthcare.